{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T03:03:40Z","timestamp":1773975820631,"version":"3.50.1"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Complications are often poorly identified and managed in cancer survivors after treatment and restoring their initial quality of life remains a challenge, particularly in a context of unequal access to care nationwide. The PASCA \u201cParcours de Sant\u00e9 au cours du Cancer [in English: healthcare pathways with cancer]\u201d feasibility study was conducted in the L\u00e9on B\u00e9rard Comprehensive Cancer Center (Lyon, France) to assess the feasibility of a complications detection program, in cancer survivors who have received intensive chemotherapy. An initial network of physicians and healthcare professionals was also set up to facilitate medical referrals after detection. The study had a high recruitment rate (83.8%) and an adherence rate of 43%. In our analysis population (<jats:italic>n<\/jats:italic>\u202f=\u202f98), 8% presented <jats:italic>de novo<\/jats:italic> dermatological, cardiological, and pneumological complications. Of these, 42 completed all program visits. Among them, the number of patients who developed a\u202f\u2265\u202fgrade 2 complication increased between the first and last visits in: nephrology (+13.9%), overweight\/obesity (+12.5%), endocrinology (+8.3%) and cardiology (+5.6%). Patient satisfaction was high (68%). The results supported the feasibility of a complication detection program and highlighted the presence of <jats:italic>de novo<\/jats:italic> complications at the first visit, as well as an increase in the number of patients developing complication in four areas between the first and last visit. In the future, after-treatment programs could be improved by increasing the motivation of the referring oncologists and patients, improving communication and by adapting the follow-up visits to take into consideration the constraints and profiles of the cancer survivors.<\/jats:p>","DOI":"10.3389\/fmed.2025.1469930","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T07:13:12Z","timestamp":1741072392000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Detection of potential complications in cancer survivors after chemotherapy and development of a regional care network: the PASCA feasibility study"],"prefix":"10.3389","volume":"12","author":[{"given":"Romain","family":"Buono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meyssane","family":"Djebali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lodie","family":"Borja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Abadie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Morisset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Sophie","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Fl\u00e9chon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Nicolas-Virelizier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Rey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yann","family":"Guillermin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souad","family":"Assaad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amine","family":"Belhabri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Lebras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9atrice","family":"Fervers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricette","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(22)00306-3","article-title":"Improved models of care for cancer survivors","volume":"399","author":"Jefford","year":"2022","journal-title":"The Lancet."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(22)00242-2","article-title":"Management of common clinical problems experienced by survivors of cancer","volume":"399","author":"Emery","year":"2022","journal-title":"The Lancet."},{"key":"ref4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.maturitas.2020.05.018","article-title":"The World Health Organization (WHO) approach to healthy ageing","author":"Rudnicka","year":"2020","journal-title":"Maturitas."},{"key":"ref5","article-title":"Cancer Survival in High-Income Countries (SURVMARK-2) project [Internet]","volume-title":"Global Cancer Observatory - International Agency for Research on Cancer","year":"2022"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1200\/JCO.2010.32.8427","article-title":"Long-term complications of lymphoma and its treatment","volume":"29","author":"Ng","year":"2011","journal-title":"J Clin Oncol."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/bjc.1990.350","article-title":"Long-term sequelae of treatment for testicular germ cell tumours","volume":"62","author":"Bissett","year":"1990","journal-title":"Br J Cancer."},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e018403","DOI":"10.1161\/JAHA.120.018403","article-title":"Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio\u2010Oncology Guidelines","volume":"9","author":"Alexandre","year":"2020","journal-title":"Journal of the American Heart Association."},{"key":"ref9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrurol.2011.26","article-title":"Complications associated with chemotherapy in testicular cancer management","volume":"8","author":"Fung","year":"2011","journal-title":"Nat Rev Urol."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","article-title":"Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines","volume":"32","author":"Lacouture","year":"2021","journal-title":"Annals of Oncology."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2215\/CJN.02780312","article-title":"Onco-Nephrology: Renal Toxicities of Chemotherapeutic Agents","volume":"7","author":"Perazella","year":"2012","journal-title":"CJASN."},{"key":"ref12","first-page":"2768","article-title":"ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume-title":"Eur Heart J","author":"Zamorano","year":"2016"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.bulcan.2016.04.005","article-title":"Consortium de d\u00e9tection et prise en charge des atteintes pulmonaires induites par la bl\u00e9omycine","volume":"103","author":"Biya","year":"2016","journal-title":"Bulletin du Cancer."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.urolonc.2014.11.012","article-title":"Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors","volume":"33","author":"Haugnes","year":"2015","journal-title":"Urol Oncol."},{"key":"ref15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/ajh.22008","article-title":"Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: results of a retrospective case review","volume":"86","author":"Figaro","year":"2011","journal-title":"Am J Hematol."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/bmt.2014.63","article-title":"Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma","volume":"49","author":"Greenfield","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"ref17","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/annonc\/mdf048","article-title":"Long-term renal function after treatment for malignant germ-cell tumours","volume":"13","author":"Foss\u00e5","year":"2002","journal-title":"Annals of Oncology."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/1097-0142(19861115)58:10<2214::AID-CNCR2820581009>3.0.CO;2-I","article-title":"The long-term effect of cisplatin on renal function","volume":"58","author":"Fjeldborg","year":"1986","journal-title":"Cancer."},{"key":"ref19","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/ckj\/sfy026","article-title":"Renal involvement in chronic lymphocytic leukemia","volume":"11","author":"Wanchoo","year":"2018","journal-title":"Clinical Kidney Journal."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3109\/10428194.2011.619606","article-title":"Obesity in adult lymphoma survivors","volume":"53","author":"Lynce","year":"2012","journal-title":"Leuk Lymphoma."},{"key":"ref21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1756-9966-31-50","article-title":"Chemotherapy and skin reactions","volume":"31","author":"Fabbrocini","year":"2012","journal-title":"J Exp Clin Cancer Res."},{"key":"ref22","year":""},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1200\/JCO.21.00277","article-title":"Dynamics of long-term patient-reported quality of life and health behaviors after adjuvant breast cancer chemotherapy","volume":"40","author":"Di Meglio","year":"2022","journal-title":"J Clin Oncol."},{"key":"ref24","article-title":"Europe\u2019s Beating Cancer Plan: A new EU approach to prevention, treatment and care [Internet]","volume-title":"European Commission.","year":"2022"},{"key":"ref25","article-title":"Survivorship and rehabilitation: policy recommendations for quality improvement in cancer survivorship and rehabilitation in EU Member States","volume-title":"European Guide on Quality Improvement in Comprehensive Cancer Control Scientific Institute of Public Health","author":"Albreht","year":"2017"},{"key":"ref26","year":"2022"},{"key":"ref27","volume-title":"La d\u00e9mographie m\u00e9dicale [Internet]. Conseil national de l\u2019Ordre des M\u00e9decins","year":"2019"},{"key":"ref28","article-title":"Direction de la recherche des \u00e9tudes","volume-title":"Rem\u00e9dier aux p\u00e9nuries de m\u00e9decins dans certaines zones g\u00e9ographiques: les le\u00e7ons de la litt\u00e9rature internationale [Internet]","year":"2021"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2466-13-35","article-title":"Differences in classification of COPD group using COPD assessment test (CAT) or modified Medical Research Council (mMRC) dyspnea scores: a cross-sectional analyses","volume":"13","author":"Kim","year":"2013","journal-title":"BMC Pulmonary Medicine."},{"key":"ref30","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1183\/09031936.00025214","article-title":"The COPD assessment test: a systematic review","volume":"44","author":"Gupta","year":"2014","journal-title":"European Respiratory Journal."},{"key":"ref31","article-title":"Risque cardiovasculaire global en pr\u00e9vention primaire et secondaire: \u00e9valuation et prise en charge en m\u00e9decine de premier recours - Note de cadrage [Internet]","volume-title":"Haute Autorit\u00e9 de Sant\u00e9.","year":"2025"},{"key":"ref32","volume-title":"Haute Autorit\u00e9 de Sant\u00e9 - Guide du parcours de soins \u2013 Maladie r\u00e9nale chronique de l\u2019adulte (MRC) [Internet]","year":""},{"key":"ref33","article-title":"Screening for Chronic Obstructive Pulmonary Disease: Evidence Report and Systematic Review for the US Preventive Services Task Force","volume-title":"JAMA [Internet]","author":"Jm","year":"2016"},{"key":"ref34","article-title":"Surpoids et ob\u00e9sit\u00e9 de l\u2019adulte: prise en charge m\u00e9dicale de premier recours [Internet]","volume-title":"Haute Autorit\u00e9 de Sant\u00e9","year":""},{"key":"ref35","article-title":"Prise en charge des dysthyro\u00efdies chez l\u2019adulte [Internet]","volume-title":"Haute Autorit\u00e9 de Sant\u00e9","year":"2025"},{"key":"ref36","article-title":"Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2 [Internet]","volume-title":"Haute Autorit\u00e9 de Sant\u00e9","year":"2025"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.purol.2020.09.026","article-title":"Recommandations pratiques pour la prise en charge du d\u00e9ficit en testost\u00e9rone","volume":"31","author":"Burte","year":"2021","journal-title":"Progr\u00e8s en Urologie."},{"key":"ref38","year":"2017"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s40814-023-01416-w","article-title":"A review of sample sizes for UK pilot and feasibility studies on the ISRCTN registry from 2013 to 2020","volume":"9","author":"Totton","year":"2023","journal-title":"Pilot and Feasibility Studies."},{"key":"ref40","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s40814-020-00634-w","article-title":"Guidance for conducting feasibility and pilot studies for implementation trials","volume":"6","author":"Pearson","year":"2020","journal-title":"Pilot and Feasibility Studies."},{"key":"ref41","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1471-2288-13-104","article-title":"An audit of sample sizes for pilot and feasibility trials being undertaken in the United Kingdom registered in the United Kingdom Clinical Research Network database","volume":"13","author":"Billingham","year":"2013","journal-title":"BMC Med Res Methodol."},{"key":"ref42","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j..2002.384.doc.x","article-title":"Design and analysis of pilot studies: recommendations for good practice","volume":"10","author":"Lancaster","year":"2004","journal-title":"J Eval Clin Pract."},{"key":"ref43","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","article-title":"General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States","volume":"107","author":"Nolte","year":"2019","journal-title":"Eur J Cancer."},{"key":"ref44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF03165081","article-title":"Chronic graft-versus-host disease and late effects after hematopoietic stem cell transplantation","volume":"76","author":"Sanders","year":"2002","journal-title":"Int J Hematol."},{"key":"ref45","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2002-08-2628","article-title":"Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation","volume":"102","author":"Mielcarek","year":"2003","journal-title":"Blood."},{"key":"ref46","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1038\/bcj.2011.14","article-title":"Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update","volume":"1","author":"Mohty","year":"2011","journal-title":"Blood Cancer Journal."},{"key":"ref47","first-page":"134","article-title":"Recognizing and managing chronic graft-versus-host disease","volume-title":"Hematology Am Soc Hematol Educ Program.","author":"Lee","year":"2008"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ajh.25764","article-title":"Treatment and disease-related complications in multiple myeloma: Implications for survivorship","volume":"95","author":"Chakraborty","year":"2020","journal-title":"American Journal of Hematology"},{"key":"ref49","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","volume-title":"ESMO Open [Internet].","author":"Conte","year":"2022"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1469930\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T07:13:25Z","timestamp":1741072405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1469930\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":49,"alternative-id":["10.3389\/fmed.2025.1469930"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1469930","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"article-number":"1469930"}}